The Open UniversitySkip to content

Histone lysine demethylases in breast cancer.

Paolicchi, Elisa; Crea, Francesco; Farrar, William L.; Green, Jeffrey E. and Danesi, Romano (2013). Histone lysine demethylases in breast cancer. Critical Reviews in Oncology/Hematology, 86(2) pp. 97–103.

DOI (Digital Object Identifier) Link:
Google Scholar: Look up in Google Scholar


Histone lysine demethylases (KDMs) have been recently discovered in mammals and have been nicknamed "erasers" for their ability to remove methyl groups from histone substrates. In cancer cells, KDMs can activate or repress gene transcription, behaving as oncogenes or tumor suppressors depending upon the cellular context. In order to investigate the potential role of KDMs in Breast Cancer (BC), we queried the Oncomine database and determined that the expression of KDMs correlates with BC prognosis. High expression of KDM3B and KDM5A is associated with a better prognosis (no recurrence after mastectomy p=0.005 and response to docetaxel p=0.005); conversely, KDM6A is overexpressed in BC patients with an unfavorable prognosis (mortality at 1 year, p=8.65E-7). Our findings suggest that KDMs could be potential targets for BC therapy. Further, altering the interactions between KDMs and Polycomb Group genes (PcG) may provide novel avenues for therapy that specifically targets these genes in BC.

Item Type: Journal Item
Copyright Holders: 2013 Elsevier
ISSN: 1879-0461
Keywords: histone lysine demethylase; KDM3B; KDM5A; KDM6A; polycomb; breast cancer
Academic Unit/School: Faculty of Science, Technology, Engineering and Mathematics (STEM) > Life, Health and Chemical Sciences
Faculty of Science, Technology, Engineering and Mathematics (STEM)
Item ID: 45792
Depositing User: Francesco Crea
Date Deposited: 13 May 2016 09:05
Last Modified: 07 Dec 2018 10:39
Share this page:


Altmetrics from Altmetric

Citations from Dimensions

Actions (login may be required)

Policies | Disclaimer

© The Open University   contact the OU